Biotech News

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Prime Medicine (PRME)Prime Medicine2026-09-24 20:01 ESTFDA / regulatory

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc.

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

PRMEPrime Medicine2026-10-05 11:59 EST

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

PRMEPrime Medicine2026-09-24 20:01 EST